Neon Bloom, Inc. (NBCO)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 630.07 Thousand USD | 87.75% |
| 2022 | 335.58 Thousand USD | -7.51% |
| 2021 | 362.83 Thousand USD | 310.67% |
| 2020 | 88.35 Thousand USD | -88.37% |
| 2019 | 759.89 Thousand USD | 6.02% |
| 2018 | 716.75 Thousand USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 64.75 Thousand USD | 0.0% |
| 2010 | 942.97 Thousand USD | 152.05% |
| 2009 | 374.11 Thousand USD | 14.98% |
| 2008 | 325.36 Thousand USD | 104.01% |
| 2007 | 159.48 Thousand USD | 0.0% |
| 2006 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 332.77 Thousand USD | -47.85% |
| 2024 Q1 | 638.13 Thousand USD | 1.28% |
| 2023 Q2 | 389.27 Thousand USD | 6.34% |
| 2023 Q1 | 366.07 Thousand USD | 9.09% |
| 2023 Q4 | 630.07 Thousand USD | 9.17% |
| 2023 FY | 630.07 Thousand USD | 87.75% |
| 2023 Q3 | 577.15 Thousand USD | 48.26% |
| 2022 Q1 | 362.27 Thousand USD | -0.15% |
| 2022 Q4 | 335.58 Thousand USD | 2.3% |
| 2022 FY | 335.58 Thousand USD | -7.51% |
| 2022 Q3 | 328.03 Thousand USD | 0.0% |
| 2021 FY | 362.83 Thousand USD | 310.67% |
| 2021 Q1 | 310 Thousand USD | 0.0% |
| 2021 Q3 | 342.14 Thousand USD | 0.96% |
| 2021 Q4 | 362.83 Thousand USD | 6.05% |
| 2021 Q2 | 338.88 Thousand USD | 9.32% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | 88.35 Thousand USD | -88.37% |
| 2019 FY | 759.89 Thousand USD | 6.02% |
| 2018 FY | 716.75 Thousand USD | 0.0% |
| 2017 FY | - USD | -100.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | 64.75 Thousand USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2011 Q1 | 719.99 Thousand USD | -23.65% |
| 2010 Q2 | 597.67 Thousand USD | 11.31% |
| 2010 Q4 | 942.97 Thousand USD | 69.63% |
| 2010 Q3 | 555.9 Thousand USD | -6.99% |
| 2010 Q1 | 536.91 Thousand USD | 43.52% |
| 2010 FY | 942.97 Thousand USD | 152.05% |
| 2009 Q2 | 378.02 Thousand USD | 13.64% |
| 2009 Q3 | 345.11 Thousand USD | -8.71% |
| 2009 FY | 374.11 Thousand USD | 14.98% |
| 2009 Q4 | 374.11 Thousand USD | 8.41% |
| 2009 Q1 | 332.65 Thousand USD | 2.24% |
| 2008 Q3 | 282.76 Thousand USD | 83.68% |
| 2008 Q4 | 325.36 Thousand USD | 15.07% |
| 2008 Q1 | 116.96 Thousand USD | -26.66% |
| 2008 Q2 | 153.94 Thousand USD | 31.61% |
| 2008 FY | 325.36 Thousand USD | 104.01% |
| 2007 Q3 | 722.96 Thousand USD | 360.3% |
| 2007 Q1 | 151.17 Thousand USD | 0.0% |
| 2007 Q4 | 159.48 Thousand USD | -77.94% |
| 2007 FY | 159.48 Thousand USD | 0.0% |
| 2007 Q2 | 157.06 Thousand USD | 3.89% |
| 2006 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 98.471% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 84.714% |
| SQZ Biotechnologies Company | 27.47 Million USD | 97.706% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 98.547% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 97.883% |
| Mesoblast Limited | 118.7 Million USD | 99.469% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 33.555% |
| Genus plc | 233.1 Million USD | 99.73% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 78.499% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 53.105% |
| Marizyme, Inc. | 18.71 Million USD | 96.634% |
| ContraFect Corporation | 2.88 Million USD | 78.13% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 15.99% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -365.046% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 56.436% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 72.911% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 88.865% |
| MultiCell Technologies, Inc. | 202.58 USD | -310926.261% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 98.904% |
| EV Biologics, Inc. | 1.49 Million USD | 57.847% |
| Q BioMed Inc. | 4.1 Million USD | 84.67% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 98.097% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 48.706% |
| Biomind Labs Inc. | 735.54 Thousand USD | 14.338% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.633% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 95.152% |
| Skye Bioscience, Inc. | 4.61 Million USD | 86.348% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 29.05% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -345.227% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 89.268% |
| IMV Inc. | 28.88 Million USD | 97.819% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -2349.85% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 72.101% |
| GB Sciences, Inc. | 1.75 Million USD | 64.186% |
| Alpha Cognition Inc. | 1.22 Million USD | 48.37% |
| HST Global, Inc. | 98.31 Thousand USD | -540.85% |
| CSL Limited | 12.18 Billion USD | 99.995% |
| Halberd Corporation | 150 Thousand USD | -320.051% |
| Enzolytics Inc. | 996.33 Thousand USD | 36.761% |
| Resverlogix Corp. | 6.49 Million USD | 90.293% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -31.953% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -146.517% |
| argenx SE | 20 Million USD | 96.85% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 98.617% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 76.739% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -6062.122% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.849% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -214.071% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 73.722% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -174.794% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.069% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 79.179% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -75.162% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 96.9% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -323.855% |
| BioStem Technologies, Inc. | 4.71 Million USD | 86.627% |
| ONE Bio Corp. | 19.71 Million USD | 96.804% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -151.847% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -153.328% |
| Agentix Corp. | 50 Thousand USD | -1160.154% |
| LadRx Corporation | 33.6 Thousand USD | -1774.894% |
| Cell Source, Inc. | 9.25 Million USD | 93.191% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 16.679% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 16.679% |
| NovAccess Global Inc. | 2.19 Million USD | 71.359% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 91.092% |
| Itoco Inc. | 228.37 Thousand USD | -175.893% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -198.65% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 87.355% |
| Kadimastem Ltd | 891.22 Thousand USD | 29.302% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -56.794% |
| CytoDyn Inc. | 30.07 Million USD | 97.905% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -30.105% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -79.077% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 91.943% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -414.349% |
| Rebus Holdings, Inc. | 310 Thousand USD | -103.251% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 86.694% |
| International Stem Cell Corporation | 4.17 Million USD | 84.919% |
| Bioxytran, Inc. | 1.92 Million USD | 67.269% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -909.528% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 71.109% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 92.423% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 92.661% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 59.493% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -135.103% |
| Neutra Corp. | 54.15 Thousand USD | -1063.448% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 65.57% |
| PureTech Health plc | 25.51 Million USD | 97.53% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 48.533% |
| IXICO plc | 472.02 Thousand USD | -33.484% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 95.935% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 98.988% |
| CSL Limited | 12.18 Billion USD | 99.995% |
| Cellectis S.A. | 92.77 Million USD | 99.321% |